检索结果-南通市图书馆

RETROGRADE ENDOURETHROTOMY WIH HOLMIUM:YAG LASER FOR TREATMENT OF URETHRAL STRICTURES

第十五届全国泌尿外科学术会议

作者： zhong wu, qiang ding, haowen jiang, wenbing luo, jiang Geng , zhaohui jiangzhong wu, qiang ding, haowen jiang, wenbing luo, jiang Geng , zhaohui jiang fuqiang wang, yuanfang zhang (Department of Urology, Huashan Hospital Affiliated to Fudan University, Shanghai , China 200040)

Objective To investigate the efficacy and safety of retrograde ureterorenoscopic incision with holmium:YAG laser for treatment of ureteral / ureteropelvic junction obstruction. Methods 61 patients ( 52 with ureteral obstruction, and 9 with ureteropelvic junction obstruction) were treated with retrograde ureterorenoscopic incision using holmium:YAG laser from May 2003-April 2008.

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

RETROGRADE ENDOURETHROTOMY WIH HOLMIUM:YAG LASER FOR TREATME...

茉莉酸合成基因正向调控番茄对晚疫病的阶段性抗性

第十五届全国泌尿外科学术会议

作者： zhong wu, haowen jiang, qiang ding, wenbing luo, Peng Gao, fuqiang wang,yuanfang zhang (Department of Urology, Huashan Hospital Affiliated to Fudan University, Shanghai , China 200040 )

Objective To evaluate the efficacy and safety of retrograde endourethrotomy with holmium:YAG laser for treatment of urethral strictures. Methods 39 patients with urethral strictures( 19 bulbar, 7membranous,7 combined,...

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

植物病理学报 2024年第4期54卷 746-755页

作者：江玉霞代丽丽薛晓婧于悦张建荔丁新华钟巍然储昭辉刘海峰作物生物学国家重点实验室山东农业大学农学院泰安271018 山东省蔬菜病虫生物学重点实验山东农业大学植物保护学院泰安271018 杂交水稻国家重点实验室武汉大学生命科学学院武汉430072 特色作物研究所重庆市农业科学院重庆401329 山东蓬勃生物科技有限公司泰安271018

由致病疫霉(Phytophthora infestans)引起的晚疫病严重危害番茄的产量和品质。番茄对晚疫病存在阶段性抗性,但具体抗性机制尚不清楚。本研究以番茄品种“小汤姆”为供试材料,发现该品种幼苗期(株龄4周)比成株期(株龄8周)更抗晚疫病。利... 详细信息

由致病疫霉(Phytophthora infestans)引起的晚疫病严重危害番茄的产量和品质。番茄对晚疫病存在阶段性抗性,但具体抗性机制尚不清楚。本研究以番茄品种“小汤姆”为供试材料,发现该品种幼苗期(株龄4周)比成株期(株龄8周)更抗晚疫病。利用RNA测序和实时荧光定量PCR技术富集并验证了幼苗期番茄茉莉酸(Jasmonic acid,JA)生物合成途径中AOS1、AOS2和AOC等基因的转录水平显著高于成株期植株。植物激素检测结果也显示,番茄叶片中JA含量在幼苗期显著高于成株期。在本生烟叶片中瞬时表达AOS1、AOS2、AOC等基因均增强了烟草对晚疫病的抗性,表明这些JA合成相关基因的表达水平和植物对晚疫病的抗性水平之间呈正相关。体外喷施茉莉酸甲酯(Methyl Jasmonate,MeJA)能提高番茄植株对晚疫病的抗性,而喷施JA合成抑制剂DIECA则使番茄更感晚疫病,进一步证明了JA正向调控番茄对晚疫病的抗性。上述结果表明,JA合成相关基因的差异表达在番茄对晚疫病的阶段性抗性中发挥着重要作用。本研究为利用阶段性抗性防治番茄晚疫病提供了重要依据。

关键词：番茄晚疫病阶段性抗性茉莉酸 AOS AOC

同方期刊数据库

Dual human iPSC-derived cardiac lineage cell-seeding extracellular matrix patches promote regeneration and long-term repair of infarcted hearts

在线全文

学校读者我要写书评

暂无评论

Bioactive Materials 2023年第10期28卷 206-226页

作者： Yun jiang Ling-Ling zhang Fan zhang Wei Bi Peng zhang Xiu-Jian Yu Sen-Le Rao Shi-Hui wang qiang Li Chen ding Ying Jin zhong-Min Liu Huang-Tian Yang Translational Medical Center for Stem Cell Therapy&Institute for Heart Failure and Regenerative Medicine Shanghai East HospitalSchool of MedicineTongji UniversityShanghai200092China CAS Key Laboratory of Tissue Microenvironment and Tumor Shanghai Institute of Nutrition and HealthUniversity of Chinese Academy of Sciences(CAS)CASShanghai200031PR China State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development School of Life SciencesInstitute of Biomedical SciencesHuman Phenome InstituteZhongshan HospitalFudan UniversityShanghai200433China Institute for Stem Cell and Regeneration CASBeijing100101PR China

Human pluripotent stem cell-derived cardiovascular progenitor cells (hCVPCs) and cardiomyocytes (hCMs) possess therapeutic potential for infarcted hearts;however, their efficacy needs to be enhanced. Here we tested the hypotheses that the combination of decellularized porcine small intestinal submucosal extracellular matrix (SIS-ECM) with hCVPCs, hCMs, or dual of them (Mix, 1:1) could provide better therapeutic effects than the SIS alone, and dual hCVPCs with hCMs would exert synergic effects in cardiac repair. The data showed that the SIS patch well supported the growth of hCVPCs and hCMs. Epicardially implanted SIS-hCVPC, SIS-hCM, or SIS-Mix patches at 7-day post-myocardial infarction significantly ameliorated functional worsening, ventricular dilation and scar formation at 28- and 90-day post-implantation in C57/B6 mice, whereas the SIS only mildly improved function at 90-day post-implantation. Moreover, the SIS and SIS-cell patches improved vascularization and suppressed MI-induced cardiomyocyte hypertrophy and expression of Col1 and Col3, but only the SIS-hCM and the SIS-Mix patches increased the ratio of collagen III/I fibers in the infarcted hearts. Further, the SIS-cell patches stimulated cardiomyocyte proliferation via paracrine action. Notably, the SIS-Mix had better improvements in cardiac function and structure, engraftments, and cardiomyocyte proliferation. Proteomic analysis showed distinct biological functions of exclusive proteins secreted from hCVPCs and hCMs, and more exclusive proteins secreted from co-cultivated hCVPCs and hCMs than mono-cells involving in various functional processes essential for infarct repair. These findings are the first to demonstrate the efficacy and mechanisms of mono- and dual-hCVPC- and hCM-seeding SIS-ECM for repair of infarcted hearts based on the side-by-side comparison.

关键词： Induced human pluripotent stem cells Cardiac lineage cells Extracellular matrix patch Cardiomyocyte regeneration Infarcted heart repair

CEPC Technical Design Report

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed Xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai Yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci Xiao-Jun Bi Yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai wujun Cai Yijian Cai Yizhou Cai Yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi Junsong Cang Guofu Cao Jianshe Cao Antoine Chance Xuejun Chang Yue Chang Zhe Chang Xinyuan Chang Wei Chao Auttakit Chatrabhuti Yimin Che Yuzhi Che Bin Chen Danping Chen Fuqing Chen Fusan Chen Gang Chen Guoming Chen Hua-Xing Chen Huirun Chen Jinhui Chen Ji-Yuan Chen Kai Chen Mali Chen Mingjun Chen Mingshui Chen Ning Chen Shanhong Chen Shanzhen Chen Shao-Long Chen Shaomin Chen Shiqiang Chen Tianlu Chen Wei Chen Xiang Chen Xiaoyu Chen Xin Chen Xun Chen Xurong Chen Ye Chen Ying Chen Yukai Chen Zelin Chen Zilin Chen Gang Chen Boping Chen Chunhui Chen Hok Chuen Cheng Huajie Cheng Shan Cheng Tongguang Cheng Yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho Ming-Chung Chu Xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui Xiaohao Cui Zhaoyuan Cui Brunella D'Anzi Ling-Yun Dai Xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng Wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran ding Siqin dingl Yadong ding Haiyi Dong Jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central China Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa Chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan China academy of engineering physics MianyangSichuan China building materials academy Beijing China Center of Advanced Science and Technology Beijing China Institute of Atomic Energy Beijing China Jiliang University HangzhouZhejiang China Nuclear Instrument CO. LTDBeijing China University of Geosciences Beijing China University of Geosciences WuhanHubei China University of Mining and Technology XuzhouJiangsu China West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing Chulalongkorn University Bangkok City University of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East China University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by China,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV Linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The Linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

Exploring an Integrative Therapy for Treating COVID-19:A Randomized Controlled Trial

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Integrative Medicine 2020年第9期26卷 648-655页

作者： wang Jia-bo wang zhong-xia JING Jing ZHAO Peng DONG Jing-hui ZHOU Yong-feng YANG Guang NIU Ming ZHAO Xu jiang Tian-jun Bl Jing-feng XU Zhe zhang Ping wu Dan BAI Zhao-fang GUO Yu-ming YU Si-miao SUN Yong-qiang zhang Zi-teng ZHAN Xiao-yan LI Peng-yan ding Jin-biao ZHAO Peng-fei SONG Xue-ai TANG Jian-yuan HE Dong-chu CHEN Zhu QIN En-qiang wang Rui-lin XIAO Xiao-he China Military Institute of Chinese Medicine The Fifth Medical Center of Chinese PLA General HospitalBeijing(100039)China Integrative Medical Center The Fifth Medical Center of Chinese PLA General HospitalBeijing(100039)China Treatment and Research Center for Infectious Diseases The Fifth Medical Center of Chinese PLA General HospitalBeijing(100039)China National Clinical Research Center for Infectious Diseases Beijing(100039)China Department of Radiology The Fifth Medical Center of Chinese PLA General HospitalBeijing(100039)China Research Center for Clinical and Translational Medicine The Fifth Medical Center of Chinese PLA General HospitalBeijing(100039)China Sichuan Evidence-Based Medicine Center of Traditional Chinese Medicine Affliated Hospital Chengdu University of Traditional Chinese MedicineChengdu(610075)China College of Life Science Beijing University of Chinese MedicineBeijing(100029)China Department of Integrated Treatment General Hospital of Central Theater CommandWuhan(430070)China

Objectives:To develop a new Chinese medicine(CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome(ARDS)in COVID-19 ***:A putative ARDS-suppressing drug Keguan-1 was first developed and then evaluated by a randomized,controlled two-arm *** two arms of the trial consist of a control therapy(alpha interferon inhalation,50(x g twice daily;and lopinavir/ritonavir,400 and 100 mg twice daily,respectively)and a testing therapy(control therapy plus Keguan-119.4 g twice daily)by random number table at 1:1 ratio with 24 cases each *** 2-week treatment,adverse events,time to fever resolution,ARDS development,and lung injury on newly diagnosed COVID-19 patients were ***:An analysis of the data from the first 30 participants showed that the control arm and the testing arm did not exhibit any significant differences in terms of adverse *** on this result,the study was expanded to include a total of 48 participants(24 cases each arm).The results show that compared with the control arm,the testing arm exhibited a significant improvement in time to fever resolution(P=0.035),and a significant reduction in the development of ARDS(P=0.048).Conclusions:Keguan-1-based integrative therapy was safe and superior to the standard therapy in suppressing the development of ARDS in COVID-19 patients.(Trial registration *** 04251871 at ***).

关键词： COVID-19 SARS-CoV-2 acute respiratory distress syndrome Chinese medicine

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-Yi Su Sun-Bin Ling Qiao-Nan Shan Xu-Yong Wei Rui wang Chang-Ku Jia Li Zhuang Tian Shen Li-Min ding Zhi-Dan Xu Lai-Bang luo Li-Bo Sun Guang-Ming Li Tai-Shi Fang Nan jiang Kun zhang Zhao-Jie Su Zhi-Hai Peng Ren Lang Tao jiang qiang He Lin-Sen Ye Yang Yang Yu-Ting He Wen-Zhi Guo Liu-Gen Lan Xu-Yong Sun Dong Chen Zhi-Shui Chen Da-Wei Zhou Shao-Jun Ye Qi-Fa Ye Min Tian Jian-Hua Shi Bo wang jiang Liu Qian Lu Wei Rao Jin-Zhen Cai Tao Lv Jia-Yin Yang Pu-Sen wang Lin zhong Jing-Sheng Ma Qi-Gen Li Sheng-Dong wu Chang-jiang Lu Cai-De Lu Dong-Hua zhang Xuan wang Zi-qiang Li Mu-Jian Teng Jun-Jie Li Wen-Tao jiang Jian-Hua Li Quan-Bao zhang Ning-Qi Zhu Zheng-Xin wang Kang He qiang Xia Shao-Hua Song Zhi-Ren Fu Wei Qiu Guo-Yue Lv Rui-Peng Song Ji-Zhou wang Zheng wang Jian Zhou Gang Chen Ying-Peng Zhao Li Li Ze-Min Hu Qi-Jie luo zhong-Zhou Si Bin Xie Xiao-Shun He Zhi-Yong Guo Shu-Sen Zheng Xiao Xu Department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China Liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic Surgery and Liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of Liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma Liver transplantation Conversion

Influence of chitosan nanofiber scaffold on porcine endogenous retroviral expression and infectivity in pig hepatocytes

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2011年第22期17卷 2774-2780页

作者： Bing Han Xiao-Lei Shi jiang-qiang Xiao Yue zhang Xue-Hui Chu Jin-Yang Gu Jia-Jun Tan zhong-Ze Gu Yi-Tao ding Department of Hepatobiliary Surgery the Affiliated Drum Tower Hospital of Nanjing University Medical SchoolNanjing 210008Jiangsu ProvinceChina Department of Hepatobiliary Surgery Drum Tower Clinical Medical College of Nanjing Medical UniversityNanjing 210008Jiangsu ProvinceChina State Key Laboratory of Bioelectronics Southeast UniversityNanjing 210000Jiangsu ProvinceChina

AIM: To investigate the influence of chitosan nanofiber scaffold on the production and infectivity of porcine endogenous retrovirus (PERV) expressed by porcine hepatocytes. METHODS: Freshly isolated porcine hepatocytes were cultured with or without chitosan nanofiber scaffold (defined as Nano group and Hep group) for 7 d. The daily collection of culture medium was used to detect reverse transcriptase (RT) activity with RT activity assaykits and PERV RNA by reverse transcription-polymerase chain reaction (PCR) and real time PCR with the PERV specific primers. And Western blotting was performed with the lysates of daily retrieved cells to determine the PERV protein gag p30. Besides, the in-vitro infectivity of the supernatant was tested by incubating the human embryo kidney 293 (HEK293) cells. RESULTS: The similar changing trends between two groups were observed in real time PCR, RT activity assay and Western blotting. Two peaks of PERV expression at 10H and Day 2 were found and followed by a regular decline. No significant difference was found between two groups except the significantly high level of PERV RNA at Day 6 and PERV protein at Day 5 in Nano group than that in Hep group. And in the in-vitro infection experiment, no HEK293 cell was infected by the supernatant. CONCLUSION: Chitosan nanofiber scaffold might prolong the PERV secreting time in pig hepatocytes but would not obviously influence its productive amount and infectivity, so it could be applied in the bioartificial liver without the increased risk of the virus transmission.

关键词： Chitosan nanofiber scaffold Porcine hepatocyte Porcine endogenous retrovirus Bioartificial liver

螺旋CT平扫结合输尿管镜诊断和治疗输尿管阴性结石

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

复旦学报（医学版） 2007年第5期34卷 764-766页

作者：姜昊文吴忠丁强张元芳复旦大学附属华山医院泌尿外科上海200040

目的讨论螺旋CT平扫结合输尿管镜/钬激光在输尿管阴性结石的诊断和治疗。方法73例排泄性尿路造影(intravenous urogram,IVU)显示肾盂积水但未见结石的患者,均进行B超和螺旋CT平扫(2mm),采用输尿管镜/钬激光碎石治疗。结果以输尿管镜检... 详细信息

目的讨论螺旋CT平扫结合输尿管镜/钬激光在输尿管阴性结石的诊断和治疗。方法73例排泄性尿路造影(intravenous urogram,IVU)显示肾盂积水但未见结石的患者,均进行B超和螺旋CT平扫(2mm),采用输尿管镜/钬激光碎石治疗。结果以输尿管镜检查结果为金标准,CT平扫的总体准确率为98.7%,明显高于超声的70.1%(P<0.001);对输尿管不同部位的结石,CT的准确率亦高于超声;输尿管镜钬激光碎石的总体成功率为95.9%。结论对IVU未显示的输尿管阴性结石推荐螺旋CT平扫并结合输尿管镜/钬激光碎石治疗。

关键词： CT 输尿管镜激光碎石结石